Canaccord analyst Bill Maughan raised the firm’s price target on Delcath Systems to $21 from $18 and keeps a Buy rating on the shares. The firm views Hepzato as an FDA-approved, soon-to-launch, multi-hundred-million peak sales opportunity. And given the company’s current ~$50M enterprise value, they believe the disconnect is a clear buying opportunity.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on DCTH:
- Largest borrow rate increases among liquid names
- Delcath announces additional $35M in funding tied to FDA approval of Hepzato Kit
- Delcath Systems price target raised to $13 from $10 at Roth MKM
- Delcath Systems price target raised to $20 from $19 at BTIG
- Delcath Systems price target raised to $18 from $17 at H.C. Wainwright
